FLT3 and acute myeloid leukemia: Combining RTK-inhibitors with non-receptor tyrosine kinase inhibitors is suggested to improve outcomes in FLT3-mutated acute myeloid leukemia in vitro and in vivo.769 But RTK-inhibitor resistance may be also overcome by targeting cytoplasmic tyrosine kinases as well.